Related Experiment Video
Updated: Jul 17, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Concepts in Ras-directed therapy
1Department of Neurobiochemistry, The George S Wise Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv 69978, Israel. kloog@ccsg.tau.ac.il
Abstract:
Ras proteins are key transducers of growth signals regulated by cell surface receptors. They are anchored to the inner surface of the cell membrane where receptor-mediated signalling induces Ras activation (GDP/GTP exchange) and inactivation (stimulation of Ras GTPase activity). Ras-GTP in turn activates a multitude of signalling cascades controlling cell growth and differentiation. Aberrant Ras function (mostly constitutive activation) contributes to the development of many types of neoplastic human diseases. Activating mutations in ras genes, leading to the expression of Ras proteins insensitive to Ras-GTPase activating proteins, are found in as many as 30% of all human tumours. This suggests that Ras is an appropriate target for drug design. Remarkable improvements in the understanding of post-translational modifications in Ras that promote Ras-membrane anchorage, in the mechanisms of activation and inactivation of Ras, and in the interactions of Ras with a plethora of effector molecules have led to the development of new concepts for Ras-directed therapy. The most advanced approach has been that of farnesyltransferase inhibitors (FTIs) designed to inhibit the farnesylation of Ras required for membrane anchorage and transforming activity. FTIs now in clinical trials have been extensively reviewed. Here we review the progress in the development of FTIs and in the development of other promising concepts for Ras-directed therapy. These include compounds such as S-farnesylthiosalicylic acid (FTS), which disrupt the proper anchorage of Ras with the cell membrane and inhibit human tumour growth in animal models, and compounds that interfere with interactions of Ras with its downstream effectors. We conclude with a description of a recently described novel drug concept that could restore the defective GTPase activity of oncogenic Ras and with the interesting results of reovirus-induced tumour regression observed in animal models of human tumours containing an intact Ras signalling pathway.
Insights
Ras proteins are crucial for cell signaling, and their aberrant function drives cancer. New therapies target Ras, including farnesyltransferase inhibitors (FTIs) and compounds disrupting Ras interactions, showing promise in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Ras proteins are central to growth factor signaling pathways, regulating cell growth and differentiation.
- Dysregulated Ras signaling, often due to activating mutations, is implicated in a significant percentage of human cancers.
- Understanding Ras post-translational modifications, activation/inactivation mechanisms, and effector interactions is key for developing targeted therapies.
Purpose of the Study:
- To review progress in developing Ras-directed cancer therapies.
- To highlight novel therapeutic strategies beyond farnesyltransferase inhibitors (FTIs).
- To discuss emerging concepts for targeting oncogenic Ras and enhancing anti-tumor immunity.
Main Methods:
- Review of current literature on Ras-targeted therapies.
- Discussion of farnesyltransferase inhibitors (FTIs) and their clinical trial status.
- Exploration of alternative strategies including S-farnesylthiosalicylic acid (FTS), effector interaction inhibitors, and novel GTPase-activating concepts.
Main Results:
- Farnesyltransferase inhibitors (FTIs) are the most advanced Ras-directed therapy, with ongoing clinical trials.
- Compounds like S-farnesylthiosalicylic acid (FTS) demonstrate efficacy in disrupting Ras membrane anchorage and inhibiting tumor growth in preclinical models.
- Novel approaches are emerging, including drugs to restore Ras GTPase activity and reovirus-mediated tumor regression in Ras-dependent cancers.
Conclusions:
- Ras remains a critical target for cancer drug development due to its central role in oncogenesis.
- Multiple therapeutic strategies targeting Ras are progressing, offering new hope for cancer treatment.
- Future directions include restoring Ras function, targeting its interactions, and leveraging viral therapies for enhanced anti-tumor effects.
Related Concept Videos
The Ras Gene
Ras is a superfamily...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
The Ras Gene
Ras is a superfamily...
Rational Emotive Behavior Therapy

